These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9573740)

  • 1. Haematological recovery after high-dose consolidation chemotherapy with peripheral blood progenitor cell rescue: the effects of the mobilization regimen and post-transplant growth factors.
    Van Hoef ME
    Neth J Med; 1998 Jan; 52(1):30-9. PubMed ID: 9573740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
    Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
    J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow.
    Benboubker L; Cartron G; Roingeard F; Delain M; Degenne M; Linassier C; Hérault O; Truglio D; Bout M; Petit A; Brémond JL; Desbois I; Colombat P; Binet C; Domenech J
    Exp Hematol; 2003 Jan; 31(1):89-97. PubMed ID: 12543111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant.
    Bolwell BJ; Goormastic M; Yanssens T; Dannley R; Baucco P; Fishleder A
    Bone Marrow Transplant; 1994 Dec; 14(6):913-8. PubMed ID: 7536072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy.
    Spitzer G; Adkins D; Mathews M; Velasquez W; Bowers C; Dunphy F; Kronmueller N; Niemeyer R; McIntyre W; Petruska P
    Bone Marrow Transplant; 1997 Dec; 20(11):921-30. PubMed ID: 9422470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
    Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
    Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
    Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous administration of G-CSF and GM-CSF for re-mobilization in patients with inadequate initial progenitor cell collections for autologous transplantation.
    Bashey A; Corringham S; Gilpin E; Fields KK; Smilee RC; DeFrancisco C; Santos-Ada O; Holman P; Carrier E; Ho AD; Lane TA; Ball ED; Janssen WE; Law P
    Cytotherapy; 2000; 2(3):195-200. PubMed ID: 12042042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
    Laughlin MJ; Kirkpatrick G; Sabiston N; Peters W; Kurtzberg J
    Ann Hematol; 1993 Dec; 67(6):267-76. PubMed ID: 7506580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer.
    Burns LJ; Weisdorf DJ; DeFor TE; Repka TL; Ogle KM; Hummer C; Miller JS
    Exp Hematol; 2000 Jan; 28(1):96-103. PubMed ID: 10658681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy.
    Waller CF; von Lintig F; Daskalakis A; Musahl V; Lange W
    Bone Marrow Transplant; 1999 Jul; 24(1):19-24. PubMed ID: 10435729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Selection of the most acceptable regimen to induce maximal tumor response and investigation of the optimal time to collect peripheral blood progenitor cells for haematological rescue after high-dose consolidation chemotherapy.
    Van Hoef ME; Baumann I; Lange C; Luft T; de Wynter EA; Ranson M; Morgenstern GR; Yvers A; Dexter TM; Testa NG
    Ann Oncol; 1994 Mar; 5(3):217-24. PubMed ID: 7514434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
    Passos-Coelho JL; Braine HG; Davis JM; Huelskamp AM; Schepers KG; Ohly K; Clarke B; Wright SK; Noga SJ; Davidson NE
    J Clin Oncol; 1995 Mar; 13(3):705-14. PubMed ID: 7533827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC).
    Benet I; Prosper BF; Marugan I; Lluch A; Arbona C; Castillo I; Solano C; Garcia-Conde J
    Bone Marrow Transplant; 1999 Jun; 23(11):1101-7. PubMed ID: 10382948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombocytopenia after high-dose chemotherapy and autologous stem cell transplantation: an unresolved problem and possible approaches to resolve it.
    Hassan HT; Zander AR
    J Hematother; 1996 Aug; 5(4):407-14. PubMed ID: 8877716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
    Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
    Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.